NIOX CEO Reshapes Shareholdings With ISA Transfers

An announcement from Circassia Pharmaceuticals ( (GB:NIOX) ) is now available.

NIOX Group plc reported that chief executive Jonathan Emms sold 69,494 ordinary shares and immediately repurchased 34,542 shares into his individual savings account, while his spouse, Sharon Emms, bought 34,539 shares into her own ISA, all executed on 20 April on London’s AIM market. Following these transactions, Emms’ total reportable holding, including shares held by his wife, stands at 3,658,498 ordinary shares, representing 0.87% of NIOX’s issued share capital, signalling a portfolio reorganisation rather than a material change in his overall economic exposure to the company.

The most recent analyst rating on (GB:NIOX) stock is a Buy with a £86.00 price target. To see the full list of analyst forecasts on Circassia Pharmaceuticals stock, see the GB:NIOX Stock Forecast page.

Spark’s Take on NIOX Stock

According to Spark, TipRanks’ AI Analyst, NIOX is a Neutral.

The score is primarily supported by strong financial quality (growth, profitability, low debt, and solid cash generation). It is held back by bearish technical signals (price below major moving averages and negative MACD) and a high P/E that is only partly offset by the dividend yield.

To see Spark’s full report on NIOX stock, click here.

More about Circassia Pharmaceuticals

NIOX Group plc is a U.K.-listed healthcare company focused on respiratory diagnostics, best known for its NIOX-branded devices that measure fractional exhaled nitric oxide to support asthma management. The group operates globally, targeting clinicians and healthcare systems seeking accurate, non-invasive tools to monitor airway inflammation and optimise respiratory treatment decisions.

Average Trading Volume: 807,102

Technical Sentiment Signal: Sell

Current Market Cap: £235.8M

Learn more about NIOX stock on TipRanks’ Stock Analysis page.